February 8, 2006Open Access

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

Key Points

Key points are not available for this paper at this time.

Abstract

Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoregional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head and neck. (ClinicalTrials.gov number, NCT00004227.)

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

James A. Bonner

Paul M. Harari

J. Giralt

Journals

New England Journal of Medicine

Actions

Institutions

University of Wisconsin–Madison

The University of Texas MD Anderson Cancer Center

University of Virginia

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider